Company Overview - Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1] Product Development - The main drug in development is Seralutinib, which is an inhaled tyrosine kinase inhibitor targeting specific pathways related to PAH and PH-ILD [1]

Gossamer Bio (GOSS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

Core Viewpoint - Gossamer Bio (GOSS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance Indicators - Gossamer Bio is projected to earn -$0.28 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 76.3% [8]. - Over the past three months, the Zacks Consensus Estimate for Gossamer Bio has increased by 5.1%, indicating a positive outlook for the company [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Gossamer Bio's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].

A downtrend has been apparent in Gossamer Bio (GOSS) lately with too much selling pressure. The stock has declined 20% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for ...

Core Viewpoint - Gossamer Bio (GOSS) has experienced a significant downtrend, with a 15.9% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - GOSS shares have faced heavy selling pressure, indicated by an RSI reading of 19.78, suggesting that the stock may soon reverse its trend [5]. - The stock's RSI value indicates it is oversold, typically defined as an RSI reading below 30, which may present entry opportunities for investors [2][3]. - The consensus EPS estimate for GOSS has increased by 17% over the last 30 days, indicating a positive trend in earnings expectations that could lead to price appreciation [5]. Group 2: Analyst Ratings and Market Position - GOSS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [6].

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.23 per share when it actually produced earnings of $0.22, delivering a surprise of -4.35%.Over the last four quarters, the c ...

BlackJack3D Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib. Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinical trials. This is what Gossamer's pipeline looked like in 2020: Harrow's Ophthalmic Pharmaceutical Brands ILEVRO. IOPIDINE 1% OPIDINE 0.5 ...

Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -4.35%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.19 per share when it actually produced a loss of $0.19, delivering no surprise. Over the last four quarters, the company ...

Loading... In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib. The analyst adds that Gossamer has strategically positioned seralutinib to enter large, underserved markets such as Japan. "We see shares trading below cash as creating an attractive entry point at current levels." Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with it ...

The company is not profitable yet but is guiding to be profitable in 2024. And revenue is increasing at an impressive pace. The stock doesn't get much analyst attention, but the four analysts that have issued a rating give MVST a consensus price target of $4.50, an 857% gain from its closing price on June 12, 2024. Source: PopTika / Shutterstock.com But all it takes is one. And that's also the number of candidates in Gossamer Bio's pipeline. The company has a candidate, Seralutinib (GB002), in a Phase 3 cli ...